XML 219 R162.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance | [1] | € 709 | € 779 | € 714
New transactions | [1] | 0 | 0 | 156
Payments made | [1] | (71) | (167) | (136)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | [1],[2] | 109 | 114 | 5
Other movements | [1] | (139) | 0 | 0
Currency translation differences | [1] | 33 | (17) | 40
Ending balance | [1] | 641 | 709 | 779
Non-current liabilities related to business combinations and to non-controlling interests |  | 569 | 501 | 674
Current liabilities related to business combinations and to non-controlling interests |  | 72 | 208 | 105
Bayer contingent purchase consideration arising from the acquisition of Genzyme |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance |  | 0 | 26 | 59
New transactions |  | 0 | 0 | 0
Payments made |  | 0 | (21) | (29)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | [2] | 0 | (5) | (9)
Other movements |  | 0 | 0 | 0
Currency translation differences |  | 0 | 0 | 5
Ending balance |  | 0 | 0 | 26
MSD contingent consideration (European vaccines business) |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance |  | 127 | 204 | 269
New transactions |  | 0 | 0 | 0
Payments made |  | (70) | (77) | (79)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | [2] | 16 | 0 | 14
Other movements |  | 0 | 0 | 0
Currency translation differences |  | (1) | 0 | 0
Ending balance |  | 72 | 127 | 204
Shire contingent consideration arising from the acquisition of Translate Bio |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance |  | 441 | 380 | 354
New transactions |  | 0 | 0 | 0
Payments made |  | 0 | 0 | 0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | [2] | 94 | 74 | 2
Other movements |  | 0 | 0 | 0
Currency translation differences |  | 33 | (13) | 24
Ending balance |  | 568 | 441 | 380
Amunix [Member] |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance |  | 137 | 165 | 0
New transactions |  | 0 | 0 | 156
Payments made |  | 0 | (69) | 0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | [2] | 0 | 45 | (2)
Other movements |  | (137) | 0 | 0
Currency translation differences |  | 0 | (4) | 11
Ending balance |  | 0 | 137 | 165
Other |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Beginning balance |  | 4 | 4 | 32
New transactions |  | 0 | 0 | 0
Payments made |  | (1) | 0 | (28)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | [2] | 1 | 0 | 0
Other movements |  | (3) | 0 | 0
Currency translation differences |  | 0 | 0 | 0
Ending balance |  | € 1 | € 4 | € 4
[1] | (a)Portion due after more than one year: €569 million as of December 31, 2024 (€501 million as of December 31, 2023 and €674 million as of December 31, 2022); portion due within less than one year: €72 million as of December 31, 2024 (€208 million as of December 31, 2023 and €105 million as of December 31, 2022).
[2] | (b)Amounts reported within the income statement line item Fair value remeasurement of contingent consideration, and mainly comprising unrealized gains and losses

X
- Definition The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2023-01-01 -Paragraph B67 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2023-01-01 -Paragraph 93 -Subparagraph e -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount recognised for new contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 3 -IssueDate 2023-01-01 -Paragraph B67 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2023-01-01 -Paragraph B67 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests. + References No definition available. + Details
Name: | sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] + References No definition available. + Details
Name: | sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease through net exchange differences business combinations and noncontrolling interests. + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (Decrease) Through Other Movements, Business Combinations And Non-Controlling Interests + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests. + References No definition available. + Details
Name: | sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_AmunixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |